

Alessandra Iurlo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1417272/publications.pdf>

Version: 2024-02-01

267
papers

4,761
citations

136740

32
h-index

143772

57
g-index

268
all docs

268
docs citations

268
times ranked

4573
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	1.7	15
2	Demystifying the diagnostic criteria of indolent systemic mastocytosis. <i>Hematological Oncology</i> , 2022, 40, 123-125.	0.8	0
3	Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 939-949.	2.3	6
4	Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. <i>Thrombosis Research</i> , 2022, 210, 67-69.	0.8	3
5	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	3.3	7
6	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563.	1.3	6
7	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
8	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. <i>Blood Advances</i> , 2022, 6, 1855-1864.	2.5	47
9	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915.	1.3	10
10	Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2587-2592.	1.1	15
11	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. <i>Cancer</i> , 2022, 128, 2449-2454.	2.0	7
12	Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis. <i>Cancers</i> , 2022, 14, 1799.	1.7	0
13	COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. <i>Haematologica</i> , 2022, 107, 1955-1959.	1.7	6
14	Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine. <i>Clinical Hematology International</i> , 2022, 4, 52-55.	0.7	7
15	Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].. <i>Journal of Clinical Oncology</i> , 2022, 40, 7061-7061.	0.8	3
16	Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 2994.	1.7	12
17	Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	39
18	Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse. <i>Leukemia and Lymphoma</i> , 2022, 63, 2743-2746.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Target Therapies for Systemic Mastocytosis: An Update. <i>Pharmaceuticals</i> , 2022, 15, 738.	1.7	3
20	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	1.7	0
21	MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7002-7002.	0.8	17
22	Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	1
23	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. <i>Current Oncology</i> , 2022, 29, 4970-4980.	0.9	2
24	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. <i>Leukemia</i> , 2021, 35, 2102-2107.	3.3	8
25	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	0.6	10
26	Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. <i>Hematological Oncology</i> , 2021, 39, 123-128.	0.8	1
27	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
28	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021, 35, 485-493.	3.3	70
29	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
30	HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases. <i>Biology</i> , 2021, 10, 152.	1.3	5
31	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	1.3	9
32	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	2.8	26
33	Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge. <i>Journal of Clinical Medicine</i> , 2021, 10, 515.	1.0	24
34	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. <i>Blood Cancer Journal</i> , 2021, 11, 53.	2.8	24
35	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	0.8	8
36	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. <i>British Journal of Haematology</i> , 2021, 193, 845-848.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 637116.	1.3	15
38	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. <i>Cancers</i> , 2021, 13, 1311.	1.7	21
39	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
40	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. <i>Leukemia</i> , 2021, 35, 2989-2993.	3.3	34
41	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. <i>Frontiers in Oncology</i> , 2021, 11, 638689.	1.3	0
42	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	2.8	9
43	Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study. <i>European Journal of Haematology</i> , 2021, 107, 436-448.	1.1	4
44	Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy. <i>Microbiology Spectrum</i> , 2021, 9, e0054921.	1.2	6
45	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	0.8	2
46	Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). <i>Annals of Hematology</i> , 2021, 100, 481-485.	0.8	11
47	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	0.8	14
48	Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 701604.	1.3	3
49	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
50	A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 978-982.	0.2	1
51	Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience. <i>Blood Cancer Journal</i> , 2021, 11, 185.	2.8	9
52	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial. <i>Blood</i> , 2021, 138, 3603-3603.	0.6	6
53	ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report. <i>Blood</i> , 2021, 138, 216-216.	0.6	0
54	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 1487-1487.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 3617-3617.	0.6	1
56	Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin. <i>Blood</i> , 2021, 138, 4381-4381.	0.6	1
57	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. <i>Blood</i> , 2021, 138, 1476-1476.	0.6	1
58	Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study. <i>Blood</i> , 2021, 138, 3408-3408.	0.6	1
59	Second <i>versus</i> First Wave of COVID-19 in Patients with MPN. <i>Blood</i> , 2021, 138, 315-315.	0.6	0
60	Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib. <i>Frontiers in Oncology</i> , 2021, 11, 734025.	1.3	0
61	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021, 138, 1474-1474.	0.6	5
62	Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 750346.	2.2	6
63	Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis. <i>Blood</i> , 2021, 138, 3624-3624.	0.6	0
64	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Blood</i> , 2021, 138, 1479-1479.	0.6	1
65	Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 819097.	1.3	2
66	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	0.8	21
67	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	3.3	35
68	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	2.0	53
69	Impact of bone marrow fibrosis grade in post ϵ polycythemia vera and post ϵ essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020, 95, E1-E3.	2.0	8
70	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
71	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
72	How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy ϵ a GIMEMA MPN WP survey. <i>Leukemia</i> , 2020, 34, 2805-2808.	3.3	16

#	ARTICLE	IF	CITATIONS
73	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	1.0	2
74	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610.	0.8	1
75	New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5805.	1.8	27
76	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020, 34, 2813-2814.	3.3	16
77	Usefulness of Dual X-ray Absorptiometry-Derived Bone Geometry and Structural Indexes in Mastocytosis. <i>Calcified Tissue International</i> , 2020, 107, 551-558.	1.5	12
78	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<math><lt;10\%</math>) or with other types of disease progression. <i>Haematologica</i> , 2020, 105, e221-e224.	1.7	8
79	Reply to "COVID-19 in persons with haematological cancers" a focus on myeloid neoplasms and risk factors for mortality. <i>Leukemia</i> , 2020, 34, 1957-1960.	3.3	26
80	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	0.8	9
81	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	2.8	6
82	Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 883.	1.3	18
83	Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous <math><sc>TKIs</sc></math>. <i>American Journal of Hematology</i> , 2020, 95, E260-E263.	2.0	15
84	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	0.6	13
85	Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy). <i>Blood Advances</i> , 2020, 4, 2996-2999.	2.5	7
86	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. <i>Leukemia</i> , 2020, 34, 2234-2237.	3.3	34
87	Management of Myelofibrosis: from Diagnosis to New Target Therapies. <i>Current Treatment Options in Oncology</i> , 2020, 21, 46.	1.3	8
88	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
89	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. <i>Blood</i> , 2020, 135, 133-144.	0.6	52
90	How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian medicines agency (AIFA). <i>Cancer Medicine</i> , 2020, 9, 4160-4165.	1.3	32

#	ARTICLE	IF	CITATIONS
91	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
92	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	0.6	61
93	Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". <i>Blood</i> , 2020, 136, 35-36.	0.6	1
94	Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients. <i>Blood</i> , 2020, 136, 42-43.	0.6	8
95	Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE) <i>TJ</i> ETQq1 1 0.78484 rgBT4Overl	0.6	0
96	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020, 136, 171-182.	0.6	65
97	Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. <i>Blood Research</i> , 2020, 55, 139-145.	0.5	2
98	Simultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
99	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
100	An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis. <i>Blood</i> , 2020, 136, 8-10.	0.6	0
101	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50.	0.6	0
102	Impact of Genetic Predisposition on Glyco-Metabolic Side Effects of TKIs in CML. <i>Blood</i> , 2020, 136, 5-5.	0.6	0
103	Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
104	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	0.8	17
105	Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin-cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. <i>PLoS ONE</i> , 2019, 14, e0218444.	1.1	9
106	â€˜Secondary chronic myeloid leukemiaâ€™™: comparison between patients previously exposed or not to chemo- and/or radiotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3584-3586.	0.6	5
107	UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E283-E285.	2.0	4
108	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. <i>Hematological Oncology</i> , 2019, 37, 424-433.	0.8	3

#	ARTICLE	IF	CITATIONS
109	Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies). <i>Expert Review of Hematology</i> , 2019, 12, 1077-1088.	1.0	6
110	Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy. <i>Annals of Hematology</i> , 2019, 98, 2609-2611.	0.8	13
111	Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key?. <i>European Journal of Haematology</i> , 2019, 103, 272-273.	1.1	24
112	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. <i>American Journal of Hematology</i> , 2019, 94, E239-E242.	2.0	3
113	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
114	Deferasirox in the management of iron overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRONEM study). <i>British Journal of Haematology</i> , 2019, 186, e123-e126.	1.2	10
115	Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study. <i>PLoS ONE</i> , 2019, 14, e0216715.	1.1	18
116	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	0.8	10
117	Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1839.	1.8	46
118	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	0.8	19
119	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
120	The Role of New Technologies in Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2019, 9, 321.	1.3	37
121	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	0.8	53
122	A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases. <i>Hematological Oncology</i> , 2019, 37, 205-211.	0.8	2
123	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	1.7	58
124	Chronic Myeloid Leukemia Patients' Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial. <i>Frontiers in Psychology</i> , 2019, 10, 329.	1.1	6
125	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	1.3	63
126	EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. <i>Journal of Experimental Medicine</i> , 2019, 216, 587-604.	4.2	36

#	ARTICLE	IF	CITATIONS
127	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	0.7	28
128	Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. <i>Blood Advances</i> , 2019, 3, 3196-3200.	2.5	18
129	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
130	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131.	6.9	45
131	Rhodotorula infection in haematological patient: Risk factors and outcome. <i>Mycoses</i> , 2019, 62, 223-229.	1.8	17
132	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
133	Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation. <i>Blood</i> , 2019, 134, 2919-2919.	0.6	2
134	Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. <i>Blood</i> , 2019, 134, 2931-2931.	0.6	2
135	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. <i>Blood</i> , 2019, 134, 29-29.	0.6	2
136	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial. <i>Blood</i> , 2019, 134, 1652-1652.	0.6	3
137	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. <i>Blood</i> , 2019, 134, 661-661.	0.6	5
138	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. <i>Blood</i> , 2019, 134, 1649-1649.	0.6	7
139	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
140	Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 496-496.	0.6	13
141	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	0.6	2
142	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0
143	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Blood</i> , 2019, 134, 4153-4153.	0.6	0
144	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. <i>Blood</i> , 2019, 134, 4142-4142.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. <i>Blood</i> , 2019, 134, 2946-2946.	0.6	0
146	Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects. <i>Blood</i> , 2019, 134, 5034-5034.	0.6	2
147	Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. <i>Annals of Hematology</i> , 2018, 97, 745-754.	0.8	11
148	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580.	0.8	32
149	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	2.0	26
150	Nilotinib induced bone marrow CD34+/lin ⁻ Ph ⁺ cells early clearance in newly diagnosed CP ⁻ chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E162-E164.	2.0	4
151	Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome ⁻ positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2516-2517.	0.6	3
152	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. <i>American Journal of Hematology</i> , 2018, 93, 615-622.	2.0	8
153	Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option. <i>Clinical Drug Investigation</i> , 2018, 38, 475-476.	1.1	19
154	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
155	Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>European Journal of Internal Medicine</i> , 2018, 52, e25-e26.	1.0	5
156	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
157	Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review. <i>Chemotherapy</i> , 2018, 63, 340-344.	0.8	5
158	An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin ⁻ TM's Lymphoma and Acute Promyelocytic Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.3	1
159	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 555.	1.3	18
160	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23
161	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 623-628.	1.0	10
162	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	1.3	84

#	ARTICLE	IF	CITATIONS
163	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7
164	Lymphocytic variant hypereosinophilia: a challenging diagnosis of a rare disease with pleomorphic clinical picture. <i>European Journal of Internal Medicine</i> , 2018, 57, e22-e24.	1.0	1
165	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
166	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018, 8, 49.	2.8	30
167	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	0.6	1
168	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018, 132, 3012-3012.	0.6	1
169	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. <i>Blood</i> , 2018, 132, 461-461.	0.6	8
170	Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter, Report from the Campus ALL/Gimema Network. <i>Blood</i> , 2018, 132, 658-658.	0.6	3
171	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	0.6	11
172	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018, 132, 1732-1732.	0.6	1
173	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	0.6	3
174	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	0.6	8
175	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	0.6	10
176	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458.	0.6	3
177	Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. <i>Oncotarget</i> , 2018, 9, 14219-14227.	0.8	13
178	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	0.6	0
179	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	0.6	0
180	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. <i>Blood</i> , 2018, 132, 1726-1726.	0.6	0

#	ARTICLE	IF	CITATIONS
181	"Secondary Chronic Myeloid Leukemia": Comparison between Patients Previously Exposed or Not to Chemo and/or Radiotherapy. <i>Blood</i> , 2018, 132, 5437-5437.	0.6	2
182	Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data. <i>Blood</i> , 2018, 132, 5118-5118.	0.6	2
183	Integrating Clinical, Morphological, and Molecular Data to Assess Prognosis in Patients with Primary Myelofibrosis: A Practical Approach. <i>Blood</i> , 2018, 132, 1766-1766.	0.6	0
184	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	0.6	0
185	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	0.6	3
186	Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment. <i>Blood</i> , 2018, 132, 5122-5122.	0.6	0
187	EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression. <i>Blood</i> , 2018, 132, 1781-1781.	0.6	3
188	Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up. <i>Blood</i> , 2018, 132, 5435-5435.	0.6	0
189	Efficacy and Safety of Bosutinib in Chronic Phase CML Patients Developing Pleural Effusion Under Dasatinib Therapy. <i>Blood</i> , 2018, 132, 5439-5439.	0.6	0
190	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkiMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. <i>Blood</i> , 2018, 132, 4251-4251.	0.6	0
191	Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single center. <i>Hematological Oncology</i> , 2017, 35, 335-340.	0.8	0
192	Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version. <i>American Journal of Hematology</i> , 2017, 92, E48-E51.	2.0	21
193	Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers. <i>American Journal of Hematology</i> , 2017, 92, E47-E48.	2.0	5
194	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805.	2.0	71
195	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
196	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2017, 99, 36-41.	1.1	3
197	Treatment of Myelofibrosis: Old and New Strategies. <i>Clinical Medicine Insights Blood Disorders</i> , 2017, 10, 1179545X1769523.	0.3	21
198	Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. <i>Cancer Biomarkers</i> , 2017, 21, 41-53.	0.8	3

#	ARTICLE	IF	CITATIONS
199	Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 1953-1954.	0.8	7
200	An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review. <i>Leukemia Research Reports</i> , 2017, 8, 7-10.	0.2	6
201	Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients. <i>Histopathology</i> , 2017, 71, 897-908.	1.6	17
202	The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations. <i>Modern Pathology</i> , 2017, 30, 169-179.	2.9	18
203	Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. <i>Pathology and Oncology Research</i> , 2017, 23, 281-286.	0.9	2
204	Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case. <i>Case Reports in Hematology</i> , 2017, 2017, 1-5.	0.3	2
205	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	0.8	14
206	Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera. <i>Medicine (United States)</i> , 2016, 95, e3697.	0.4	8
207	Thrombopoietin/TGF- β 1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. <i>Stem Cells</i> , 2016, 34, 1123-1133.	1.4	49
208	Anagrelide and Mutational Status in Essential Thrombocythemia. <i>BioDrugs</i> , 2016, 30, 219-223.	2.2	7
209	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.4	13
210	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	2.3	24
211	Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. <i>Haematologica</i> , 2016, 101, e267-e268.	1.7	7
212	CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis. <i>Annals of Hematology</i> , 2016, 95, 1965-1969.	0.8	7
213	Reply To: Assessment of Liver and Spleen Stiffness in Patients With Myelofibrosis Using FibroScan and Shear Wave Elastography. <i>Ultrasound Quarterly</i> , 2016, 32, 317-317.	0.3	0
214	Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2712-2715.	0.6	20
215	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.4	6
216	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. <i>PLoS ONE</i> , 2016, 11, e0156990.	1.1	3

#	ARTICLE	IF	CITATIONS
217	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
218	Next-generation sequencing for sensitive detection of <i>BCR-ABL1</i> mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. <i>Oncotarget</i> , 2016, 7, 21982-21990.	0.8	52
219	Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study. <i>Blood</i> , 2016, 128, 5434-5434.	0.6	0
220	The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells. <i>Blood</i> , 2016, 128, 3080-3080.	0.6	0
221	Age and <i>d</i> PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. <i>American Journal of Hematology</i> , 2015, 90, 910-914.	2.0	181
222	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. <i>American Journal of Hematology</i> , 2015, 90, 970-974.	2.0	2
223	Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?. <i>Oncotarget</i> , 2015, 6, 33944-33951.	0.8	59
224	Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib. <i>Annals of Hematology</i> , 2015, 94, 1749-1751.	0.8	7
225	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. <i>Leukemia Research</i> , 2015, 39, 525-529.	0.4	17
226	Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2015, 94, 881-882.	0.8	16
227	Essential Thrombocythemia: The Dermatologic Point of View. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 739-747.	0.2	21
228	Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre. <i>British Journal of Haematology</i> , 2015, 170, 890-892.	1.2	16
229	Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications. <i>Modern Pathology</i> , 2015, 28, 1448-1457.	2.9	23
230	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. <i>Blood</i> , 2015, 126, 2775-2775.	0.6	3
231	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. <i>Blood</i> , 2015, 126, 2792-2792.	0.6	2
232	BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?. <i>Blood</i> , 2015, 126, 346-346.	0.6	12
233	Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases. <i>Blood</i> , 2015, 126, 5279-5279.	0.6	3
234	Patients with Unexplained Thrombosis Require a Prompt Investigation to Search a Chronic Myeloproliferative Neoplasm (MPN), Even If Platelet Count Is $<600 \times 10^9/L$. Analysis on 129 Patients from Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2015, 126, 5181-5181.	0.6	0

#	ARTICLE	IF	CITATIONS
235	REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data. <i>Blood</i> , 2015, 126, 1597-1597.	0.6	0
236	Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters. <i>Blood</i> , 2015, 126, 2489-2489.	0.6	2
237	Echocardiography and Cardiopulmonary Exercise Testing for Early Detection of Pulmonary Hypertension in Primary Myelofibrosis. <i>Blood</i> , 2015, 126, 4066-4066.	0.6	0
238	Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2015, 126, 4071-4071.	0.6	0
239	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015, 126, 1582-1582.	0.6	0
240	GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment. <i>Blood</i> , 2015, 126, 3645-3645.	0.6	0
241	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015, 126, 1598-1598.	0.6	0
242	Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Network study. <i>American Journal of Hematology</i> , 2014, 89, E200-5.	2.0	42
243	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014, 167, 541-546.	1.2	47
244	Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2014, 38, 294-298.	0.4	32
245	Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. <i>European Journal of Internal Medicine</i> , 2014, 25, 63-66.	1.0	24
246	Successful Treatment With Imatinib in a Patient With Chronic Eosinophilic Leukemia Not Otherwise Specified. <i>Journal of Clinical Oncology</i> , 2014, 32, e37-e39.	0.8	7
247	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.4	30
248	Imatinib and ruxolitinib association: first experience in two patients. <i>Haematologica</i> , 2014, 99, e76-e77.	1.7	26
249	Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. <i>Oncotarget</i> , 2014, 5, 4665-4670.	0.8	28
250	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013, 31, 103-109.	0.8	59
251	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	1.3	36
252	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	13.9	664

#	ARTICLE	IF	CITATIONS
253	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. Blood, 2013, 122, 4068-4068.	0.6	10
254	The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Modern Pathology, 2012, 25, 1193-1202.	2.9	99
255	The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. Blood, 2012, 120, 1678-1678.	0.6	14
256	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. Blood, 2012, 120, 1748-1748.	0.6	1
257	A Large-Scale Trial Testing the Intensity of Cyto-reductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). Blood, 2012, 120, 4-4.	0.6	3
258	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. Blood, 2011, 118, 2770-2770.	0.6	1
259	Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT),. Blood, 2011, 118, 3836-3836.	0.6	1
260	A Case of Congenital Red Cell Pyruvate Kinase Deficiency Associated with Hereditary Spherocytosis. Blood, 2011, 118, 5272-5272.	0.6	0
261	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786.	0.6	5
262	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. Blood, 2011, 118, 4445-4445.	0.6	0
263	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elderly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. Blood, 2011, 118, 2751-2751.	0.6	1
264	Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood, 2008, 111, 1862-1865.	0.6	78
265	Essential Thrombocythemia: Analysis of Risk Factors for Thrombotic Events in a Series of 306 Patients.. Blood, 2005, 106, 4937-4937.	0.6	0
266	Bone Marrow Erythroid Maturation and Cytokine Production in Refractory Anemia Patients with Positive Mitogen-Stimulated-Direct Antiglobulin Test.. Blood, 2005, 106, 4898-4898.	0.6	0
267	Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone. , 1997, 56, 126-128.		32